Deal notes
This is an ATM facility event. The capacity shown is not cash raised.
Transaction overview
01Nasus Pharma Ltd disclosed an at-the-market program event: facility established. Authorized capacity is $8.5M. This event does not record cash proceeds raised.
- Financing type
- ATM
- Announcement date
- —
- SEC disclosure date
- Sep 18, 2026
- Agreement date
- Sep 18, 2026
- Pricing date
- —
- Closing date
- —
- Filing date
- Sep 18, 2026
- Status
- Announced
- Market cap before SEC disclosure
- $39.1M
- Prior closing price
- $3.53
- Raise as % of market cap
- —
Market data · FMP
- Historical market cap
- $39,078,716
- Market date
- Sep 17, 2026
- Closing price
- $3.53
- Latest reported shares outstanding
- 8,612,906
- Latest reported float shares
- 2,850,070
- Share-data date
- Sep 30, 2026
Market cap and closing price are from FMP for the date shown. Shares are FMP’s latest available snapshot, dated separately. Updated Sep 30, 2026.
Financial Modeling Prep ↗Financing terms
02At-the-market program
- Capital event
- Facility established
- Authorized capacity
- $8.5M
- Proceeds raised
- Not reported as raised
- Shares sold
- —
- Average sale price
- —
- Relevant period
- Not applicable
- Sales commission
- —
Fees & transaction economics
03- Placement agent / underwriting fee
- —
- Agent fee amount
- —
- Management fee
- —
- Other offering expenses (estimated)
- —
- Net proceeds (estimated)
- —
- Net proceeds as % of gross
- —
Fee amounts reflect disclosed inputs. Unknown expense components are not assumed to be zero.
Sales agent commission up to 3% of gross proceeds; a ceiling, not a fixed rate.
Transaction participants
04Source documents
05SEC filings, exhibits and attributed market data. The report separates disclosed facts, calculated metrics, and unknown terms.
Filing evidence & original calculations
8500000
Ordinary Shares having an aggregate offering price of up to $8,500,000Original source ↗
Sales agent commission up to 3% of gross proceeds; a ceiling, not a fixed rate.
We will pay the Sales Agent a commission up to 3% of the gross proceeds for any Ordinary Shares sold hereunder.Original source ↗
FMP reported market cap; as of 2026-09-17.
{"provider": "FMP", "symbol": "NSRX", "date": "2026-09-17", "marketCap": 39078716}Original source ↗